STAT3 induces anti-hepatitis C viral activity in liver cells
- PMID: 15474458
- DOI: 10.1016/j.bbrc.2004.09.081
STAT3 induces anti-hepatitis C viral activity in liver cells
Abstract
Hepatitis C virus (HCV) infection is a leading cause a of chronic liver disease worldwide. The main therapeutic regimen is the combination of interferon alpha (IFN) and the nucleoside analog, Ribavirin. IFN initiates an intracellular antiviral state by the JAK-STAT signaling pathway, including a presumed role for STAT1 and STAT2. We have previously shown that the STAT3 activation occurs during IFN treatment of human hepatoma cells, suggesting that the STAT3-mediated pathway is relevant to IFN-induced antiviral activity. In this study, we investigate the role of activated STAT3 in the induction of anti-HCV activity in human hepatoma cells. We demonstrate that the STAT3 activation is involved in efficient IFN-induced anti-HCV activity. Using an inducible, cytokine-independent, STAT3 activation system, in which the entire coding region of STAT3 is fused with the ligand-binding domain of the estrogen receptor, we demonstrate that: activated STAT3 is tightly regulated in a stably transfected cell line by an estrogen analog, 4-HT; activated STAT3 initiates efficient anti-HCV activity in a HCV subgenomic replicon cell line; and activation of STAT3 is associated with the induction of a potential antiviral gene, 1-8U. In addition, we show that the cytokine IL-6, a potent STAT3 activator, inhibits HCV subgenomic RNA replication through STAT3 activation and ERK pathway. These results strongly suggest that STAT3 activation is capable of initiating intracellular antiviral pathways.
Similar articles
-
Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line.Hepatology. 2003 May;37(5):1180-8. doi: 10.1053/jhep.2003.50184. Hepatology. 2003. PMID: 12717400
-
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.Oncogene. 2003 Jul 3;22(27):4150-65. doi: 10.1038/sj.onc.1206479. Oncogene. 2003. PMID: 12833138
-
Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.Antiviral Res. 2005 Jan;65(1):23-34. doi: 10.1016/j.antiviral.2004.09.002. Antiviral Res. 2005. PMID: 15652968
-
Ribavirin: recent insights into antiviral mechanisms of action.Curr Opin Drug Discov Devel. 2001 Sep;4(5):651-6. Curr Opin Drug Discov Devel. 2001. PMID: 12825459 Review.
-
microRNA control of interferons and interferon induced anti-viral activity.Mol Immunol. 2013 Dec;56(4):781-93. doi: 10.1016/j.molimm.2013.07.009. Epub 2013 Aug 23. Mol Immunol. 2013. PMID: 23962477 Review.
Cited by
-
Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.Virol J. 2005 Sep 7;2:80. doi: 10.1186/1743-422X-2-80. Virol J. 2005. PMID: 16146571 Free PMC article.
-
Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus.PLoS One. 2012;7(10):e46631. doi: 10.1371/journal.pone.0046631. Epub 2012 Oct 22. PLoS One. 2012. PMID: 23110054 Free PMC article.
-
Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants.Vaccines (Basel). 2020 Jun 17;8(2):313. doi: 10.3390/vaccines8020313. Vaccines (Basel). 2020. PMID: 32560440 Free PMC article. Review.
-
Kupffer Cell Metabolism and Function.J Enzymol Metab. 2015;1(1):101. Epub 2015 Aug 14. J Enzymol Metab. 2015. PMID: 26937490 Free PMC article.
-
Signaling pathways involved in liver injury and regeneration in rabbit hemorrhagic disease, an animal model of virally-induced fulminant hepatic failure.Vet Res. 2010 Jan-Feb;41(1):2. doi: 10.1051/vetres/2009050. Epub 2009 Sep 3. Vet Res. 2010. PMID: 19726019 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous